Elanco Animal Health price to free cash flow ELAN

Market value divided by free cash flow over the last twelve months, since 2019.

Today, Oct 23, 2026: 29.7×
7-year median: 30.7×
Against its 7-year history: 46th; percentile: 0 is its lowest day, 100 its highest
7-year range: 10.5× to 130×
Peer median: 46.0×

Elanco Animal Health's price to free cash flow is 29.7× as of Oct 23, 2026.

That is below its 7-year median of 30.7×, close to the middle of its last 7 years.

Over that time it ranged from 10.5× in Feb 2023 to 130× in Feb 2020.

The median for 10 large drugmakers of a similar size is 46.0×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	29.7×	29.2×	46.2×
2025	30.5×	10.6×	31.4×
2024	15.7×	14.4×	61.9×
2023	24.8×	10.5×	25.6×
2022	11.0×	10.6×	42.3×
2021	n/m a value too high to mean anything
2020	59.1×	46.1×	130×
2019	120×	41.9×	120×

Against its peers

Companies in Drug Manufacturers - General nearest Elanco Animal Health's size, closest first, today.

Company	Price to free cash flow
ELANElanco Animal Health	29.7×
BMRNBiomarin Pharmaceutical	14.7×
CORTCorcept Therapeutics	86.8×
JAZZJazz Pharmaceuticals	8.7×
PTGXProtagonist Therapeutics	68.6×
TGTXTG Therapeutics	477×
ALKSAlkermes plc.	33.0×
AMRXAmneal Pharmaceuticals	50.9×
LGNDLigand Pharmaceuticals	46.0×
KNSAKiniksa Pharmaceuticals International	32.7×
INDVIndivior Pharmaceuticals	n/m
Peer median	46.0×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Elanco Animal Health

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.